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Proximal spinal muscular atrophy (SMA) is a common auto-
somal recessive disorder –with an incidence of 1/6000 to
1/10000 live births– which results from degeneration and
loss of the alpha-motor neurons in spinal cord anterior horn
cells. Clinical manifestations include proximal muscular
weakness and atrophy and, as a consequence, scoliosis,
respiratory failure and death. SMA patients can be classified
into three groups based on age at onset, achieved mile-
stones and life span [1,2]. Type I SMA (Werding-Hoffman
disease) is the most severe form with clinical onset before 6
months. Type II SMA is the intermediate form with onset be-
fore 18 months. Type III SMA (Wohlfast-Kugelberg-We-
lander disease) is the mild form of the disease with onset af-
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Abstract
Spinal muscular atrophy (SMA) is an autosomal recessive
neuromuscular disease characterized by degeneration and
loss of motor neurons of the anterior horn of the spinal cord.
The clinical manifestations include proximal symmetric
weakness and progressive muscle atrophy. The identifica-
tion of the SMN1 gene as determinant of SMA has opened
alternative ways of studying the disease. Absence of SMN1
(either by deletion or conversion) was detected in the major-
ity of patients and subtle mutations were described in a mi-
nority. SMN1 absence was associated with a wide spectrum
of manifestations, from congenital disease to asymptomatic
cases. Modifier factors, such as the number of copies of
SMN2, its homologous copy present in all patients, could in-
fluence the phenotype and help to find a treatment for the
disease. The SMN gene is expressed in various neuronal
populations, although only motor neurons are responsible
for the manifestations of the disease. The SMN protein is part
of a complex with various proteins involved in the splicing re-
action. This apparently essential function of all cells is critical
for motor neurons, and warrants further research to eluci-
date the mechanisms of disease. 
Resum
L’atròfia muscular espinal (AME) és una malaltia neuromus-
cular autosòmica recessiva caracteritzada per Ia degen-
eració i Ia pèrdua de Ies motoneurones de Ia banya anterior
de Ia medul·la espinal. Les manifestacions clíniques més
característiques són una debilitat proximal simètrica i una
atròfia muscular progressiva. La identificació del gen SMN1
com a gen determinant de I’AME obre noves alternatives per
a I’estudi de Ia malaltia. En Ia majoria dels pacients es de-
tecta I’absència del gen SMN1 (ja sigui per deleció o per
conversió), però també se n’han identificat mutacions pun-
tuals en un petit percentatge. L’absència del gen SMN1
s’associa a un ampli espectre de manifestacions clíniques,
que van des de formes congènites de Ia malaltia fins a ca-
sos asimptomàtics. Diferents factors modificadors, com el
nombre de còpies del gen SMN2 – el gen homòleg present
tant en controls com en malalts – poden modificar el fenotip
i a Ia vegada ser útils per investigar un tractament eficaç.
Tot i que el gen SMN s’expressa en diferents poblacions
neuronals, només Ies motoneurones són Ies responsables
de Ies manifestacions de Ia malaltia. La proteïna SMN forma
part d’un complex amb altres proteïnes que participen en Ia
reacció d’empalmament i aquesta funció, essencial per a
totes Ies cèl·lules, sembla ser crítica per a Ies neurones mo-
tores. Cal aprofundir en I’estudi dels mecanismes que con-
dueixen a I’atròfia muscular espinal.
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ter 18 months. An adult form of the disease occurs with on-
set after 30 years, most patients being mildly affected (SMA
type IV or adult form). The biological bases for understand-
ing the degeneration and loss of motor neurons remain to be
clarified and there is no specific therapy to alleviate or to
cure the disease. 
Recent advances in our understanding of the genetic
bases of childhood SMA will considerably improve the clini-
cal management of the disease and help develop novel
strategies for the prevention of motor neuron degeneration.
The SMA locus
The three clinical forms of the disease were mapped to the
5q13 region [3,4]. This region contains an inverted repeat
harboring several genes: survival motor neuron (SMN) [5],
neuronal apoptosis-inhibitor protein (NAIP) [6], p44 (subunit
of basal transcription factor TFIIH) [7,8] and SERF1/ H4F5
[9] (Figure 1). Given the large number of repeated se-
quences, pseudogenes, and retro-transposable elements,
this is a very unstable region, often prone to unequal re-
arrangements between highly homologous elements, result-
ing in deletions, duplications or gene conversion events. 
Telomeric SMN (SMNt or SMN1) and centromeric SMN
(SMNc or SMN2) genes differ by five nucleotide changes
(three are exonic, located within exons 6, 7 and 8, and two
are intronic) [5, 10, 11] and both copies are composed of
nine exons, which encode identical amino acid sequences
and span approximately 20 kb. 
The NAIP gene contains 17 exons, and is present as a
telomeric functional copy, a pseudo NAIP copy, and several
truncated copies in the SMA region. NAIP is also duplicated
either with exon 5 (NAIPtel) or without exon 5 (NAIP Cen). 
The p44 gene is deleted at a frequency similar to NAIP al-
though its role in the disease is unknown [7,8]. Recently, a
new gene located at the 5´end of the SMN gene has been
identified and this has been considered as a candidate phe-
notypic modifier for SMA [9]. This gene (H4F5 or SERF1)
contains the polymorphic marker 212 and appears to be
deleted in most of the type I chromosomes compared with
type II, III or non-SMA chromosomes. 
Molecular pathology of the SMN1 gene 
Approximately 90% of patients suffering from different forms
of SMA are homozygously deleted for both copies of the
SMN1 gene exons 7 and 8 [14], whereas homozygous dele-
tions of SMN2 seem to have no clearly demonstrated clinical
consequences. A small number of SMA patients show ho-
mozygous deletions of SMN Tel exon 7 but not exon 8. In
these patients hybrid genes were characterized, most of
them being the result of gene conversion events in which
exon 7 of SMN2 was fused to exon 8 of SMN1 [13 and refer-
ences therein]. Further studies have found gene conver-
sions in type II and III patients homozygously deleted for
SMN exon 7 and 8, which explains why an apparently equal
genotype could manifest different clinical phenotypes [14].
It has been proposed that deletion events are predominant
in severe SMA chromosomes while conversions are associ-
ated with mild SMA chromosomes [15]. 
In the cases where the SMN1 gene is present, subtle mu-
tations have been detected, indicating that the SMN1 gene
is the determining gene. Lefebvre et al. [5] detected two mi-
crodeletions in splicing sites of introns 7 and 8. In the Span-
ish population, a frameshift 4 bp deletion in exon 3 (430del4)
has been detected [16]. Subsequently, another microdele-
tion in exon 3 of the SMN1 gene and an 11 bp duplication in
exon 6 (800 ins 11) producing a premature stop codon have
been described [17,18]. Moreover, missense mutations
have also been reported [12] (Figure 2).
In a recent study [19], we analyzed 364 families (168 type
I, 118 type II and 78 type III) looking for mutations in the
Figure 1. Scheme of the SMA locus in 5q13. The SMA locus consists of two inverted repeated elements containing four genes. Markers C212
and C272 are located at the 5´end of both SMN genes.
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SMN1 gene. Of these patients, 308 (85%) had deletions of
the exon 7 and 8 of the SMN1 gene; centromeric-telomeric
hybrid genes were detected in 18 patients (5%); 8 cases
(2%) showed the 4 bp deletion in exon 3 (430del4) and final-
ly, one type II case, showed an 11 bp duplication in exon 6.
No mutation has been identified to date in the remaining 28
patients (7%). All the types of mutations described were as-
sociated with the three different phenotypes. The 430del4
was detected in two type I cases, three type II and three type
III cases. Haplotype analysis of chromosomes bearing the
4 bp deletion revealed a single origin of this mutation in the
eight Spanish families. 
Genotype-phenotype correlation. Modifier genes
Although mutations of the SMN1 gene are associated with
SMA, no obvious genotype-phenotype correlation has been
observed since the absence of SMN1 exon 7 and/or 8 oc-
curs in patients with either the severe form (type I) or the
milder forms (type II and type III) (Figure 3). The fact that se-
vere type I SMA is associated with a higher frequency of ho-
mozygous deletions (approximately 45%) compared with
the milder forms (12-18% of type II and III patients) suggests
a partial involvement of NAIPtel in the SMA phenotype.
Moreover, onset and the mean age of death occur earlier in
patients where SMN1 and NAIPtel are absent [20]. However,
the contribution of NAIP to the final phenotype of SMA is still
unknown. The comparison of clinical data with the patient
genotype (SMN, NAIP and p44) showed that large-scale
deletions involving all these loci are observed in the majority
of type I patients, although smaller rearrangements involving
the SMN1 gene alone can still result in a severe phenotype.
Moreover, homozygous deletions of NAIP or p44 genes
have been observed in healthy controls unrelated to the
SMA families [6,8]. The H4F5 or SERF1 gene maps 6.5 kb
upstream of exon 1 for both SMN1 and SMN2 and contains
the C212 marker in its last intron. Almost 94% of SMA chro-
mosomes are deleted for one or both copies of C212 and
therefore for the SERF1 gene. Recent studies indicate that
SERF is a nuclear protein in HeLa and COS-1 cells (particu-
larly in nucleoli) although it is not associated with the SMN
complex [21]. The nucleolar localization coupled with dele-
tion data suggests that SERF1 could be a candidate pheno-
typic modifier of SMA patients.
The SMN2 gene is always present in SMA patients and al-
lows them to express a certain amount of SMN protein [22].
Interestingly, no patient has been diagnosed with a homozy-
gous absence of both SMN1 and SMN2 genes, implying that
the total absence of SMN would be lethal in utero. Most
SMN2 transcripts lack exon 7, and are thus functionally de-
fective, reinforcing the view that the disease is the result of
an insufficient amount of intact SMN protein. Analysis of par-
ents and patients with type II and III forms has shown that
these individuals have on average a larger number of SMN2
copies than type I patients [22, 23]. These findings indicate
that the homozygous absence of SMN1 is the result of a true
deletion in type I cases and a gene conversion in type II or III
cases. However, the correlation between the number of
SMN2 genes and the clinical phenotype is not absolute. It
Figure 2. Location of mutations described in the SMN1 gene.
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has been reported in a few SMA families whose index cases
had the chronic form of the disease (type II and III) that «un-
affected» siblings and parents are also carriers of a homozy-
gous absence of SMN1 [24,25]. However, minimal manifes-
tations and EMG abnormalities have been detected in some
of these cases, indicating the wide range of manifestations
of the disease [26] (Figure 3). Different phenotypes have
also been found in the families with the 430del4 mutation:
one homozygous (430del4/430del4) daughter was minimal-
ly affected in one consanguineous family while her three ho-
mozygous sisters were wheelchair-bound since infancy
[19]. They had the same number of SMN2 copies, indicating
that modifier genes outside the SMA locus were also respon-
sible for the phenotype. 
The SMN protein 
The SMN encodes a 38 kD protein, which bears no resem-
blance to any other proteins in the database. A tight correla-
tion between the level of SMN protein and the severity of the
disease has been observed in tissues and cells derived from
SMA patients [22,27]. A number of observations indicate
that SMN could be involved in RNA metabolism. First, a clus-
tering of missense mutations in the SMN gene has been de-
scribed in SMA patients in a region of amino acids 262-279
containing a tyrosine/glycine-rich motif which is present in
various RNA binding proteins [28]. Secondly, the SMN pro-
tein has been located by immunohistochemistry in a novel
structure termed «gems», which is more commonly associ-
ated with coiled bodies. Ramon y Cajal described the coiled
bodies in 1903, and there is considerable evidence that both
structures are involved in RNA metabolism [29]. The role of
SMN appears to be related to two essential cellular process-
es such as the biogenesis of spliceosomal U snRNPs and
the pre-mRNA splicing [30-32]. The SMN binds to itself, to
Gemin2, (former SIP1 or SMN interacting protein 1) and to
small nuclear RNPs U1 and U5 of the spliceosome, the cat-
alytic core of the splicing reaction. Recently, Gemin3 and
Gemin4 were reported as components of the SMN complex
[33,34]. Mutant forms of the SMN such as the deletion of
exon 7 and the Y272C are incapable of joining and regener-
ating snRNPs [35]. The interaction of SMN with these pro-
teins possibly plays an important role in the assembly of
snRNPs in the cytoplasm and in the nuclear regeneration of
snRNPs and spliceosomes. In the light of these observa-
tions, SMN must have a critical function for all cells. If SMN is
only necessary in large amounts in motor neurons, it could
either play an alternative role in these cells or just require a
high quantity for splicing factors. 
Expression of SMN and the mechanism of neuron
degeneration and death in SMA
The expression of the SMN gene has been detected in the
motor neurons of the spinal cord as well as in different neu-
ronal populations such as sensory neurons of the dorsal root
ganglia, neurons of the medulla oblongata, Purkinje cells of
the cerebellum and pyramidal cells of the cortex [36]. This
expression is present in the spinal cord at 8 weeks of fetal
life, and throughout postnatal and adult life. The sharp ex-
pression of SMN in the motor neurons of the human spinal
cord, the target cells in SMA, indicate that this gene is impli-
cated in neuronal development and in the pathogenesis of
the disease (Figure 4). SMA is caused by a reduction in SMN
levels, which leads to the loss or degeneration of only part of
a specific neuronal group. It can be hypothesized that the
GENOTYPE
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Figure 3. Different phenotypes reported in association with homozygous absence of the SMN1 gene under the influence of modifier genes. 
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other neuronal groups and tissues are protected by un-
known genetic or cellular factors when SMN is interrupted.
Recent studies in human fetal spinal cord suggest that the
programmed neuron death is enhanced in SMA during de-
velopment, which results in a loss of approximately half of
the neurons at birth. However, morphologic changes in mo-
tor neurons such as peripheral displacement of the nuclei or
central reduction in the number of Nissl corpuscles consis-
tent with early central chromatolysis [37], were observed
only postnatally. Given that most of the SMA motor neurons
in the neonatal period appear with pathologic findings that
had been undetected at earlier stages, it can be hypothe-
sized that type I SMA results in differential age-dependent
responses, leading to cell death and motor neuron degener-
ation during development [38]. Further investigation is nec-
essary to attribute the function of SMN in RNA biogenesis to
a possible mechanism involving cell death increase in fetal
SMA spinal cord or motor neuron degeneration. The devel-
opment of animal models is necessary to test these hypothe-
ses.
Animal models
In mice, where the SMN gene exists as a single copy, the to-
tal loss of the SMN gene due to homologous recombination
results in massive cell death in the early blastocyst stage, a
period which corresponds to the initiation of embryonic RNA
transcription [39]. The massive cell death detected in these
SMN-deficient mouse embryos reinforces the previous hy-
pothesis that the complete absence of SMN1 and SMN2 is
lethal in humans [5], thereby lending support to the crucial
role of SMN. Recently, four studies have described the de-
velopment of SMN-deficient mice models that mimic human
SMA. Two different research groups [40,41] have generated
mice with a different number of transgenic copies of SMN2,
developing a phenotype resembling severe SMA type I (one
or two copies of SMN2) or milder forms (up to 8 copies) of
the disease. Monani et al. [40] observed that neuron death
appeared after birth in the final stages of the disease. There
are neither degenerative changes in motor neurons nor
signs of skeletal muscle denervation in mice dying at 6 days
of life, suggesting that an acute degenerative process could
occur. However, given that some mice died shortly after
birth, degenerative changes in the motor neurons could be-
gin in the fetal stages. Jablonka et al. [42] reported a SMN
heterozygous mouse with reduced levels of SMN protein
without signs of denervation or motor defect, showing post-
natal loss of spinal and facial motor neurons until month 6,
decreasing thereafter. Finally, Frugier et al. [43] developed a
conditional deletion of the murine exon 7, generating a
mouse with a reduced life expectancy consistent with chron-
ic SMA (type II and III). These authors reported severe skele-
tal muscle denervation with morphological changes in motor
neurons such as indentation in the motor neuron nuclear
membranes and nuclear fragmentation despite the absence
of motor neuron loss. The latter finding suggests that there
was an apoptotic process and that motor neuron loss was a
late manifestation of the disease in these animals. These
changes had not been reported in human SMA, and the au-
thors attributed them to early events of neuronal degenera-
tion that subsequently led to motor neuron loss.
Perspectives
The identification of the gene defect in SMA has opened up
new possibilities of studying and diagnosing the disease.
Aside from the advances in the characterization of molecu-
lar defects in SMA patients, the possibility of preventing,
stopping or reversing motor neuron degeneration based on
the knowledge of the SMN function is eagerly awaited. An
interesting therapeutic alternative is upregulation or overex-
pression of the SMN2 gene, which is present in all SMA pa-
tients [44]. SMN2 produces a partially functional protein that
could alleviate the severity of the disease. Moreover, prelim-
inary results indicate that a full-length SMN expression can
be restored from SMN2 after stimulation in vitro with Htra2-
b1, a serine/arginine-rich splicing factor [45]. High through-
put drug screenings are in progress to identify compounds
that activate or replace SMN protein. Furthermore, studies
are currently being undertaken to target and deliver SMN
protein to motor neurons in vivo, develop efficient gene ther-
apy vectors to motor neurons, and to confirm the hypothesis
that stem cell transplantation can replace lost motor neu-
rons.
Figure 4. In situ hybridization of the anterior horn of human adult
spinal cord showing a motor neuron with positive signal of SMN
messenger RNA detected with an antisense SMN S35 riboprobe (hy-
brid RNA-RNA). Toluidine blue, 600x.
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